Eversense® Non-adjunctive Use Post Approval Study
← catalyst calendarSponsored by Senseonics, Inc. (industry) · SENS — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Other
Enrollment
925estimated
Sites
23
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-04-13 | actual | When the study began enrolling |
| Primary completion | 2026-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes
Interventions
- Device: Blood glucose meter
- Device: Eversense CGM System
Primary outcome
what the primary-completion date above is the date OFIncidence of moderate and severe hypoglycemic and diabetic ketoacidosis events
measured First 6 months (phase 1) compared to second 6 months (phase 2)
Permalink · SENS's whole pipeline · Catalyst calendar · Every registered study · What changed